BioSpace News Archive

Cell and Gene Therapy

June 21, 2024
All News

June 21, 2024
Featured

June 21, 2024
Deals

Tectonic Completes Reverse Merger With Avrobio, Starts Trading on Nasdaq

The combined company began trading Friday under the Nasdaq symbol TECX. A $130 million private placement was also completed, with a cash runway into mid-2027.

June 21, 2024
·
2 min read
·
Kate Goodwin
Drug Development

Zealand Deepens Weight-Loss Portfolio With Strong Phase Ib Data for GLP-1 Alternative

Zealand Pharma’s petrelintide cut body weight by more than 8% on average, with a good overall safety and tolerability profile.

June 21, 2024
·
2 min read
·
Tristan Manalac
Deals

Vanda Turns Down Cycle, Future Pak Offers as Proposals ‘Undervalue’ Company

Vanda Pharmaceuticals has rejected two unsolicited takeover offers, saying that they are “opportunistic attempts” to acquire the biotech at a heavily discounted price.

June 21, 2024
·
2 min read
·
Tristan Manalac
Drug Development

Jazz’s Tremor Drug Candidate Flops in Phase II Study, Misses Primary Endpoint

Jazz Pharmaceuticals’ calcium channel modulator suvecaltamide in a mid-stage trial was unable to significantly lower tremor burden in patients with essential tremor, the company reported Thursday.

June 21, 2024
·
2 min read
·
Tristan Manalac
FDA

Expanded Approval of Sarepta’s Elevidys Is Progress, But More Needed for DMD Patients

While Thursday’s label expansion and traditional approval for the gene therapy is an important milestone, many challenges still face the Duchenne muscular dystrophy community.

June 21, 2024
·
3 min read
·
Greg Slabodkin
Drug Development

Vertex Finally Reaches Pricing Deal With England’s NHS for Cystic Fibrosis Drugs

Vertex Pharmaceuticals’ three cystic fibrosis drugs—Kaftrio/Trikafta, Symkevi and Orkambi—will now be available through England’s National Health Service, following the signing of a long-term reimbursement agreement.

June 21, 2024
·
2 min read
·
Tristan Manalac
Pharm Country

Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease

Ocugen, Inc. today announced that the Data and Safety Monitoring Board (DSMB) for the OCU410ST GARDian clinical trial recently convened and approved to proceed with dosing the high dose of OCU410ST in the dose-escalation phase of the study.

June 21, 2024
·
6 min read